A retrospective study found that a radiomic-clinicopathologic nomogram performed better than other tools in predicting biochemical recurrence-free survival after surgery for prostate cancer.
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
C. Andrew Kistler, MD, PharmD, examines existing data about bariatric surgery and the risk for subsequent colorectal cancer development.
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
A recent wave of approvals has transformed the treatment landscape in non-small cell lung cancer with the most common EGFR mutations— EGFR exon 19 or exon 21 L858R- substitution mutations—giving clinicians a choice between 6 different interventions in the metastatic setting.
Vitamin D is a biomarker of interest in the pancreatic cancer setting.
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.
Although the risk for breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) has been well-documented, patients considering breast implants continue to be inadequately informed of the propensity for disease development.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
A systematic review of studies focused on strategies to improve patient comfort and compliance with radiotherapy treatment plans, finding that aromatherapy strategies show promise in this setting.
Bradley McGregor, MD, clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key topics in RCC care in 2021.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
The National Comprehensive Cancer Network’s updated Clinical Practice Guidelines in Oncology for multiple myeloma newly include 3 new selinexor-containing regimens.